Date published: 2025-10-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

2′,3′-Dideoxyinosine (CAS 69655-05-6)

0.0(0)
Write a reviewAsk a question

Alternate Names:
Didanosine
Application:
2′,3′-Dideoxyinosine is a potent anti-retroviral agent that acts by competing with natural dATP
CAS Number:
69655-05-6
Purity:
≥97%
Molecular Weight:
236.23
Molecular Formula:
C10H12N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

2′,3′-Dideoxyinosine, also known as ddI, has been a subject of extensive scientific research, particularly in the fields of virology and nucleic acid biochemistry. This compound has been primarily studied for its unique mechanism of action as a nucleoside analog reverse transcriptase inhibitor (NRTI). Specifically, ddI interferes with the replication of retroviruses, such as HIV, by inhibiting the reverse transcriptase enzyme essential for viral DNA synthesis. This inhibition occurs through competitive incorporation of ddI into the growing viral DNA chain, which leads to premature termination of DNA synthesis, thereby preventing viral replication. Moreover, ddI has been utilized as a molecular tool in elucidating the mechanisms of nucleic acid synthesis and DNA polymerase function. Studies have employed ddI to investigate the kinetics and fidelity of DNA polymerases, as well as to explore the structural basis of nucleoside analog incorporation into DNA. Additionally, research has utilized 2′,3′-dideoxyinosine (ddI) in studies aimed at understanding the mechanisms of viral resistance. Investigations have focused on identifying mutations in the reverse transcriptase enzyme that confer resistance to ddI, providing insights into the molecular basis of antiretroviral resistance.


2′,3′-Dideoxyinosine (CAS 69655-05-6) References

  1. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs).  |  Sluis-Cremer, N., et al. 2000. Cell Mol Life Sci. 57: 1408-22. PMID: 11078020
  2. Didanosine.  |  Shelton, MJ., et al. 1992. Ann Pharmacother. 26: 660-70. PMID: 1350471
  3. Targeted therapy of human immunodeficiency virus-related disease.  |  Mitsuya, H., et al. 1991. FASEB J. 5: 2369-81. PMID: 1712326
  4. Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.  |  Moreno, S., et al. 2007. Drugs. 67: 1441-62. PMID: 17600392
  5. Pancreatic involvement in human immunodeficiency virus infection.  |  Bonacini, M. 1991. J Clin Gastroenterol. 13: 58-64. PMID: 2007747
  6. Chromatographic methods for the bioanalysis of antiviral agents.  |  Riley, CM., et al. 1990. J Chromatogr. 531: 295-368. PMID: 2258420
  7. DIDANOSINE RETINAL TOXICITY.  |  Haug, SJ., et al. 2016. Retina. 36 Suppl 1: S159-S167. PMID: 28005674
  8. Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker®.  |  Brandsma, I., et al. 2022. Toxicol Lett. 362: 50-58. PMID: 35569722
  9. Drug-Induced Acute Pancreatitis in Adults: Focus on Antimicrobial and Antiviral Drugs, a Narrative Review.  |  Del Gaudio, A., et al. 2023. Antibiotics (Basel). 12: PMID: 37887196
  10. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.  |  Balzarini, J. 1994. Pharm World Sci. 16: 113-26. PMID: 8032337

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

2',3'-Dideoxyinosine, 1 mg

sc-205098
1 mg
$40.00

2',3'-Dideoxyinosine, 5 mg

sc-205098A
5 mg
$146.00